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[ABSTACT] 
BACKGROUND: Whole-body cancer screening with multimodalities including [F-18] -fluorodeoxyglucose 
positron emission tomography (FDG-PET) detects a wide range of tumors. This program has been recognized as 
an option of opportunistic screening, particularly in Japan. However, reports on diagnostic accuracy have been 
limited. We aimed to evaluate the detectability and related properties of this screening program among 
asymptomatic individuals in a community setting.  
METHODS: Study participants were 1,762 residents of Osaka Prefecture, Japan, who underwent opportunistic 
cancer screening at Higashitemma Clinic for the first time between November 2004 and December 2005. 
FDG-PET cancer screening was performed with several imaging modalities (e.g., FDG-PET, computed 
tomography, magnetic resonance imaging, ultrasonography), and fecal occult blood test. Screening records were 
linked to the Osaka cancer registry within one year after the screening to determine sensitivity, specificity and 
positive predictive values. 
RESULTS: After excluding 12 participants with cancer detected before the screening, 33 were identified by the 
cancer registry to have primary cancers. Of these, the present screening program detected that 28 were positive 
(6 prostate, 5 lung, 5 colorectal, 5 thyroid, 3 liver, 4 others). Sensitivity, specificity and positive predictive values 
were 84.8% (28/33, 95% confidence interval : 69.1 to 93.3), 86.8% (1,491/1,718, 85.1 to 88.3) and 10.1% 
(28/277, 6.4 to 12.9), respectively.  
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CONCLUSIONS: FDG-PET cancer screening with multimodalities reasonably and accurately detects existing 
asymptomatic cancer. However, the numbers of false negatives and false positives were not insignificant. 
Facilities that provide the screening should inform participants of relevant information, including the limitations 




The diagnostic accuracy of FDG-PET cancer screening with multimodalities for asymptomatic adults have been 
unknown in a community setting. This study revealed that the sensitivity, specificity were 84.8%, 86.8%, 
respectively. 
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To reduce cancer-related mortality, improving cancer screening is highly prioritized in all developed 
countries [1-3]. Population-based screening for gastric, uterine, lung, colon, and breast cancer are provided 
officially in Japan [4]. Besides, many other cancer screening programs are offered privately [5-7]. [F-18] 
-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging, which is used for patients with cancer, 
can detect a wide range of tumors [8, 9]. This technology has been also used to screen for cancer in 
asymptomatic adults, but this effectiveness is not currently well evaluated. As of 2011, approximately 100 
facilities in Japan provided FDG-PET as a private and opportunistic screening program [10].  
  Because the sole use of FDG-PET imaging to screen cancer has several limitations [11], the practice 
guidelines for FDG-PET cancer screening in Japan recommend that it be used alongside other modalities [12]. 
Therefore, FDG-PET cancer screening typically comprises whole-body FDG-PET in addition to other modalities 
such as computed tomography (CT), magnetic resonance imaging (MRI), ultrasonography (US), fecal occult 
blood test (FOBT) and tumor markers. This combined screening process is called “FDG-PET cancer screening 
with multimodalities.”  
By using these multimodalities, many types of cancer in various organs can be detected in a single 
examination (detection rate, 0.7-2.1% [13-20]), but admittedly, reports on diagnostic accuracy has been limited. 
In terms of the diagnostic validity of screening in asymptomatic participants, only Nishizawa et al. reported 
sensitivity and specificity of FDG-PET cancer screening with multimodalities, (81.8% and 82.0%, respectively 
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[21]). However, their study population was restricted to employee volunteers at one company, with a mean age 
of 46.7 years, which was considerably younger than what is considered the susceptible age for cancer. To 
facilitate discussion on the role and limitations of FDG-PET cancer screening with multimodalities, more data 
from studies of community-dwelling adults who more accurately represent potential participants of this program 
are necessary. 
To determine the diagnostic accuracy of FDG-PET cancer screening with multimodalities for diverse 
participants, we conducted the present study at a private facility for medical examination in a community and 
used population-based cancer registry data as the reference.  
 
STUDY PARTICIPANTS AND METHODS 
Ethical Statement  
The study protocol was approved by the ethics committee of Kyoto University Graduate School and 
Faculty of Medicine (E1339). Information regarding the use of screening data and handling of personal 
information was posted on the clinic homepage as well as in the waiting room. Participants were informed that 
data would be used for academic purposes only, and refusal of participation was assured if desired.  
 
Participants 
 Participants were 1,762 residents of Osaka prefecture, Japan, who underwent FDG-PET cancer 
screening with multimodalities for the first time at Higashitemma Clinic, one of the private facilities that provide 
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FDG-PET cancer screening with multimodalities in Japan, from November 2004 to December 2005, regardless 
of age and past cancer screening histories. The participants were charged approximately $2,000 to undergo the 
screening, which was nearly equal to the amount of medical fee reimbursement for these tests in Japan. 
Participants understood this and participated autonomously in this screening program. Written informed consent 
was obtained from all participants. 
 
Cancer Screening  
FDG-PET cancer screening with multimodalities covered whole-body FDG-PET, chest and abdominal 
CT, brain and pelvic MRI, thyroid, abdominal, and breast US and FOBT. The tumor markers were measured as a 
way to provide additional information (Table 1). When levels of these tumor markers exceeded the normal 
ranges but were not accompanied by abnormal image findings, detailed examinations were not conducted 
immediately after the screening, but were re-examined after several months. We did not use upper 
gastrointestinal series and gastroscopy but did measure Helicobacter pylori antigen and serum pepsinogen for 
detecting atrophic gastritis. 
 
Image Acquisition 
Whole-body FDG-PET studies were performed on a PET (Allegro, Phillips Medical Systems) or a 
PET-CT scanner (Discovery ST, GE Healthcare). The participants fasted for more than 4 hours and subsequently 
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received an injection of 3.7 MBq/kg FDG. The scan was started 50 minutes after the FDG injection and 
performed from the base of the skull to the proximal thigh. Chest and upper abdominal CT scans were performed 
using an X-ray CT (LightSpeed Ultra 16, GE Healthcare) or PET-CT scanner without contrast media (3.75 mm 
slices; 512 × 512 matrix size; FOV 50 cm). MRI was performed using a 1.5T MRI device (Intera 1.5T, PHILIPS; 
Signa EchoSpeed Plus EXCITE Xi 1.5T, GE Healthcare) without contrast media. Transaxial T1-, T2- and 
FLAIR images of the brain, and transaxial T1-, T2- and fat-saturation T2 (for men), transaxial T1-, T2-, sagittal 
T2- (for women) images were taken of the pelvis. Thyroid, abdominal, or breast US was performed using a 
LOGIQ 7 Discovery system (GE Healthcare). 
 
Image interpretation  
PET, CT, and MRI imaging data were acquired by radiological technologists and interpreted by two 
highly experienced radiologists. Trained clinical laboratory technicians performed all examinations and 
generated key images for all US examinations and one well-experienced ultrasound radiologist followed up with 
their interpretation. Imaging reports were created by referencing images taken by other modalities and materials.  
 
Integrated diagnosis and report 
A physician wrote up an integrated diagnosis based on radiologist reports and biochemical test results. 
The participants suspected to have cancer were advised to receive a definitive diagnosis at another hospital. 
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Record Linkage 
The use of population-based cancer registries as the reference has been widely accepted when 
assessing the accuracy of cancer screening programs [22-25]. We linked all screening results with data from a 
population-based cancer registry in Osaka (Osaka Cancer Registry). The Osaka Cancer Registry has been in 
operation since December 1962 and covers the entire Osaka Prefecture (population of 8.86 million, as of the 
2010 census) [26]. The Cancer Registry registers cancer case reports sent from hospitals or clinics as well as 
death certificates from healthcare centers as computer files. These files contain all essential data relevant to 
participants with cancer and deaths in the resident population of Osaka Prefecture. Data from the Osaka Cancer 
Registry during the period between January 2004 and December 2006 were used for the analysis. References 
used for individual identification included name, sex, birth date, and address [27]. Registry data for participants 
with cancer included cancer origin, histopathology findings, stage, and date of diagnosis.  
The participants who had been diagnosed with cancer before screening were excluded from this 
analysis. 
 
Test performance values 
Presence of cancer at screening was defined as cancers that were confirmed within one year of 
screening. The rationale for this was that FDG-PET cancer screening with multimodalities targets various types 
of cancers and the one-year definition is used widely in other population-based cancer screenings in Japan, 
including that for gastric, colorectal, and lung cancer [4]. 




The present study primarily used descriptive data analysis (i.e., sensitivity, specificity, positive 
predictive values for FDG-PET cancer screening with multimodalities and FDG-PET alone). 95% confidence 
intervals (CIs) of these proportions were obtained according to the Wilson method using the Web calculator 
provided by the Oxford Center of Evidence-based Medicine [28]. All data are reported according to the STARD 




A total of 1,762 residents (males, 1,073; females, 689) underwent FDG-PET cancer screening with 




Of the 1,762 participants, 12 were excluded due to previous cancer diagnoses. There identified 277 
sites with suspected cancer in 254 of the 1,750 participants. Of these, 232 participants had one site with 
suspected cancer, 21 had two sites, and 1 had three sites. Of the 254 participants with cancer suspicions, 28 
primary cancer sites among the 27 participants were pathologically confirmed as true-positive (including one 
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case with two cancer sites). Of the 1,496 participants who were screened as free from cancer suspicion, five 
primary cancer regions were noted by the cancer registry, but confirmed as false-negative cases (Figure 1). 
Sensitivity, specificity and positive predictive values were 84.8% (28 of 33), 86.8% (1,491 of 1,718) and 10.1% 
(28 of 277), respectively, for FDG-PET cancer screening with multimodalities (Table 3). Specifically, the false 
negative rate was 15.2% (5 of 33) and the false positive rate was 13.2 % (227 of 1,718). FDG-PET alone 
suspected the presence of 106 sites with cancer among 106 of the 1,750 participants, 19 of which were identified 
as true-positives. Among 1,644 participants who were screened to be free from suspected cancer, 14 primary 
cancer regions were identified among 13 participants as false-negatives (including one case with two cancer 
sites) (Figure 1). Sensitivity, specificity and positive predictive values were 57.6% (19 of 33), 94.9% (1,631 of 
1,718) and 17.9% (19 of 106), respectively, for FDG-PET alone (Table 4). 
Details for 33 sites of cancer identified by the Osaka Cancer Registry are shown in Table 5. The 
number of true-positive and false-negative sites was 28 and five, respectively. Of these, one individual showed 
two sites of cancer (No. 16 and No. 22 in Table 5). Of the 28 true-positive sites, one distant metastatic case was 
identified, while the others were early stage. The prevalence of cancer by age group was high in participants in 
their 60s to 70s. 
 
DISCUSSION 
The present study revealed the diagnostic accuracy of the FDG-PET cancer screening with 
multimodalities in a community setting with linking to the population-based cancer registry data. Sensitivity 
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values for FDG-PET cancer screening with multimodalities and FDG-PET alone were 84.8% and 57.6%, 
respectively, while specificity values were 86.8% and 94.9%, respectively. These findings confirmed that the risk 
of false-negatives by FDG-PET alone screening was reduced by adding multimodalities to FDG-PET, albeit with 
slightly lower specificity due to the cumulative false-positive cases [30]. 
Although integration of various modalities is the main advantage of FDG-PET cancer screening, some 
consideration is required when evaluating sensitivity and specificity. Sensitivity and specificity results for 
FDG-PET cancer screening with multimodalities should be carefully interpreted because the calculation method 
differs from that of the usual single modality screening. While the main advantage of FDG-PET cancer screening 
with multimodalities is the ability to detect a wide range of cancer types in various organs concurrently, this 
capability also makes it difficult to evaluate the sensitivity, and especially the specificity, of screening. In general, 
cancer screening is site-specific, but FDG-PET cancer screening with multimodalities targets all organs. This 
means that one or more sites with suspected cancer can be detected in one participant. According to the number 
of cancer cases and sites confirmed by the cancer registry data, we calculated “the number of cases without 
cancer” in the screening. However, “the number of sites without cancer” cannot be calculated. Considering these 
properties of FDG-PET cancer screening with multimodalities, we calculated the sensitivity using the number of 
cancer sites and the specificity using the number of participants. 
In addition, the sensitivity and specificity of FDG-PET cancer screening with multimodalities differ 
by characteristics of study populations and combination materials with FDG-PET. These issues need critical 
interpretations when comparing the present findings with that of a similar study. Actually, the findings of 
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Nishizawa et al. were derived from a group of confined and young employees (mean age, 46.7 years) at one 
company [21]. None of their participants were detected to have colorectal cancer, the most detectable cancer by 
FDG-PET cancer screening with multimodalities. Nishizawa explained this discrepancy by stating that most 
participants had received annual health check-ups including FOBT and that some of them were excluded from 
their study. In contrast, the present participants were general community-living adults (mean age, 55.0 years); 
consequently, many kinds of cancer including five colorectal cancers were detected, in a manner consistent with 
other previous studies. Furthermore, the selection of combination materials affects the sensitivity and specificity. 
Nishizawa et al. examined other combination with FDG-PET in terms of sensitivity/specificity and concluded 
that imaging modalities with PSA was the best. Based on their combination materials (which excluded FOBT), 
we recalculated our results, which changed the sensitivity and specificity values of 84.8% to 72.7% and 86.8% to 
91.9%, respectively. This shows that it is necessary to consider study populations and combination materials in 
comparison.  
This screening potentially detects not only fatal cancers but also non-fatal cancers like thyroid cancer, 
that even stop growing and/or. In the present results, five of 28 true-positive cases were thyroid cancers. 
Detection of these indolent cancers may increase unnecessary definitive examinations and deteriorate 
participants’ quality of life [31]. This means that the effectiveness of cancer screening should not be evaluated 
only by the number of detectable cases of cancers in the screening. It is desirable to confirm a reduction in 
mortality rates among the population in which screening is applied, especially for official organized screening 
programs. The levels of sensitivity and specificity for a cancer screening program represent indirect evidence of 
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its effectiveness [32]; thus, to establish FDG-PET cancer screening with multimodalities as an option of private 
opportunistic screening, the sensitivity and specificity of the program must be determined. 
The potential risk of screening modalities/materials are an important factor to consider when 
determining the combination. As many imaging modalities involve radiation, radiation exposure is 
understandably an important concern. This is especially true for Japanese people, because the frequency of 
diagnostic X-ray usage in Japan is the highest among all developed countries [33]. Radiation dose with 
FDG-PET is estimated to be 4.2 mSv (0.019 mSv per MBq × 60 kg×3.7 MBq) [34], equivalent to the dose used 
for X-ray diagnosis of gastric cancer (3.7-4.6 mSv) [35]. Gotbi et al. estimated that effective radiation dose for 
PET-CT was 6.34-9.48 mSv (at 60 kg body weight) in a single whole-body scan, and surmised that many healthy 
individuals exposed to at least 6.34 mSv would not benefit from the screening if found to be without cancer [36]. 
Murano et al. estimated radiation exposure as well as the risks and benefits of FDG-PET in cancer screening and 
concluded that FDG-PET cancer screening was potentially beneficial for examinees, but this benefit varied by 
age, gender, and the type of examination (PET or PET-CT) [37]. Although FDG-PET cancer screening with 
multimodalities is an opportunistic screening based on individual preference, the use should not be expanded to 
the younger populations which possess a relatively low risk of cancer.  
The potential risk of screening modalities/materials are an important factor to consider when selecting 
the combination tools. In this study, two cases of gastric cancer were false-negative. However, these participants 
were instructed to undertake definitive examinations due to suspicions of chronic atrophic gastritis. In Japan, 
population-based screening for gastric cancer is conducted using a barium X-ray examination, which inevitably 
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results in radiation exposure. Some facilities that provide FDG-PET cancer screening with multimodalities use 
gastrofiberscopy to avoid additional radiation exposure [18], but this is invasive. Our program included neither 
barium X-ray examination nor gastrofiberscopy to detect gastric cancer. Instead, we used Helicobacter pylori 
antigen and the serum pepsinogen test to detect chronic atrophic gastritis, the pre-cancerous stage of gastric 
cancer [38, 39]. The inclusion of a barium X-ray examination or gastrofiberscopy critically affects the sensitivity 
of this screening program. Further examination is required to select an optimal combination of 
modalities/materials that also takes into account participant preference and cost.   
 
This study has some limitations. First, this was a single-facility study. However, study participants 
were recruited from a variety of regions in Osaka Prefecture and participated autonomously in the screening. 
This setting was consistent with other private facilities for FDG-PET cancer screening in Japan. Furthermore, 
participant age distribution was similar to that observed in the general FDG-PET cancer screening facilities in 
Japan [18], so a significant age-related bias was not likely. A second limitation was that participants who visited 
hospitals outside of Osaka Prefecture were not followed. However, 60 hospitals designated as regional cancer 
centers are capable of administering cancer care in Osaka [40], and all participants were expected to visit one of 
these hospitals. The Osaka Cancer Registry, the quality of which has been assured by the International Agency 
for Research on Cancer (IARC), has been utilized widely for research [22, 23, 41, 42] and covers all of these 
facilities, so the possibility of leaked records was very low. The third limitation concerns the definition of 
false-negative cases. In this study, the presence of cancer at screening was defined as the diagnosis of cancer 
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within one year of screening and identified in the cancer registry, just as other studies did [22, 23]. Some cancer 
cases may not have been diagnosed within the year; in fact, our extended follow-up for another year identified 
two other cancer cases. Based on this finding, the sensitivity of FDG-PET cancer screening with multimodalities 
was recalculated, which changed the value from 84.8% to 82.9%. However, an extended follow-up period may 
introduce the risk of detecting “de novo” cancer developing after the screening. 
FDG-PET cancer screening with multimodalities is an innovative method, and thus accuracy, technical 
properties, safety, efficacy and/or effectiveness and economic attributes need to be assessed when applying this 
technique to screen asymptomatic populations [43]. At present, the materials and imaging modalities combined 
with FDG-PET vary slightly by facility, so reports on the accuracy of the screening from more facilities are 
necessary. Furthermore, from the perspective of screening service quality, a system that constantly reviews the 
screening accuracy using their own facility data needs to be established. Population-based cancer rregistries 
provide assessors of the screening program with reliable external references for that purpose.  
 
CONCLUSIONS 
FDG-PET cancer screening with multimodalities detected existing asymptomatic cancer with 
reasonable accuracy. However, numbers of false-negative and false-positive results were not negligible. While 
this method serves as one option for opportunistic screening based on individual preference, facilities should 
inform participants of the relevant information, including limitations of this program.  
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FIGURE LEGENDS 
Figure 1. Flow diagram for study participant recruitment and data collection 
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TABLES 
Table 1. Tumor markers 
Tumor markers Normal Range 
Carcinoembryonic antigen (CEA) ≤5.0 ng/ml  
Alpha-fetoprotein (AFP) ≤10.0 ng/ml 
Carbohydrate antigen 19-9 (CA19-9) ≤37.0 U/ml  
Squamous cell carcinoma antigen (SCC) ≤1.50 ng/ml  
Cytokeratin-19 fragment (CYFRA) ≤3.5 ng/ml  
Pro-gastrin releasing peptide (Pro-GRP) ≤45.9 pg/ml  
Prostate-specific antigen (PSA) [Male] ≤4.0 ng/ml  
Carbohydrate antigen 125 (CA125)[ Female] ≤35.0 U/ml  
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Table 2. Participant characteristics (N = 1,762) 
 Male   Female Total 
Population 1,073 689      1,762  
（%） 60.9% 39.1%  100.0%  
Mean age (years) 55.2  54.6  55.0  - 
Standard deviation 10.8  11.0  10.9  - 
    (%) 
10-19 1 0 1 0.1 
20-29 2 9 11 0.6 
30-39 98 62 160 9.0 
40-49 224 146 370 20.8 
50-59 335 225 560 31.4 
60-69 325 193 518 29.1 
70-79 85 51 136 7.6 
80-89 3 3 6 0.3 
BMI, kg/m2     
    (%) 
-18.5 28 74 102 5.8 
18.5-22.0 197 313 510 28.9 
22.0-25.0 440 186 626 35.5 
25.0-30.0 364 103 467 26.5 
30.0- 44 13 57 3.2 
Blood glucose (ml/dl)     
    (%) 
-100 554 414 968 54.9 
100-200 507 273 780 44.3 
200- 12 6 18 1.0 
Smoking status     
    (%) 
Smoker 442 155 597 33.9 
Nonsmoker 629 533 1162 65.9 
Unknown 2 1 3 0.2 
Abbreviations: BMI, body mass index.  
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Cancer (+) Cancer (-) 
Test result 
Positive 
Site 28 249 277 
Participant 27 227 254 
Negative 
Site 5 - - 
Participant 5 1,491 1,496 
Total 
Site 33 - - 
Participant 32 1,718 1,750 
Sensitivity,% (95% CI) 84.8, (69.1 - 93.3) [28/33] 
Specificity, % (95% CI) 86.8 (85.1 - 88.3) [1,491/1,718]  
Positive predictive value, % (95% CI) 10.1 (6.4 - 12.9) [28/277]  
Abbreviations: FDG-PET, [F-18] -fluorodeoxyglucose positron emission tomography; CI, confidence interval. 
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Cancer (+) Cancer (-) 
Test result 
Positive 
Site 19 87 106 
Participant 19 87 106 
Negative 
Site 14 - - 
Participant 13 1,631 1,644 
Total 
Site 33 - - 
Participant 32 1,718 1,750 
Sensitivity, % (95% CI) 57.6 (40.8 - 72.8) [19/33] 
Specificity, % (95% CI) 94.9 (93.8 - 95.9) [1,631/1,718] 
Positive predictive value, % (95% CI) 17.9 (11.8 - 26.3) [19/106] 
Abbreviations: FDG-PET, [F-18] -fluorodeoxyglucose positron emission tomography; CI, confidence interval.
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Table 5. Characteristics of 33 cancers identified by record linkage 





Positive findings  
in other modalities 
Time to cancer 
diagnosis (months) 
1 Male 65 Prostate cancer Adenocarcinoma Localized Positive Positive Pelvic MRI, PSA 3 
2 Male 72 Prostate cancer Adenocarcinoma Localized Positive Positive Pelvic MRI, PSA 11 
3 Male 76 Prostate cancer Adenocarcinoma Localized Positive Normal Pelvic MRI, PSA 3 
4 Male 61 Prostate cancer Adenocarcinoma Localized Positive Normal Pelvic MRI, PSA 2 
5 Male 67 Prostate cancer Adenocarcinoma Localized Positive Normal Pelvic MRI, PSA 3 
6 Male 55 Prostate cancer Adenocarcinoma Localized Positive Normal Pelvic MRI, PSA 2 
7 Male 63 Prostate cancer Adenocarcinoma Localized Negative Normal PSA 10 
8 Male 63 Lung cancer Bronchioloalveolar Carcinoma Localized Positive Positive Chest CT 3 
9 Male 69 Lung cancer Carcinoid Localized Positive Positive Chest CT 4 
10 Female 66 Lung cancer Squamous cell carcinoma Localized Positive Positive Chest CT 2 
11 Male 71 Lung cancer Alveolar cell carcinoma Regional lymph node metastasis Positive Positive Chest CT, CYFRA 1 
12 Male 61 Lung cancer Adenocarcinoma Regional lymph node metastasis Positive Positive Chest CT, CEA 3 
13 Man 61 Colorectal cancer Adenocarcinoma Regional lymph node metastasis Positive Positive FOBT 2 
14 Female 39 Colorectal cancer Adenocarcinoma In situ Positive Positive  4 
15 Male 66 Colorectal cancer Adenocarcinoma Localized Positive Positive FOBT 2 
16 Male 57 Colorectal cancer Adenocarcinoma Localized Positive Normal FOBT 2 
17 Male 58 Colorectal cancer Adenocarcinoma Localized Positive Normal FOBT 2 
18 Male 54 Thyroid cancer Adenocarcinoma Localized Positive Positive Thyroid US 8 
19 Female 61 Thyroid cancer Adenocarcinoma Adjacent organ involvement  Positive Positive Thyroid US 8 
20 Male 49 Thyroid cancer Adenocarcinoma Adjacent organ involvement  Positive Positive Thyroid US 9 
21 Female 66 Thyroid cancer Adenocarcinoma Regional lymph node metastasis Positive Normal Thyroid US 4 
22 Male 57 Thyroid cancer Adenocarcinoma Regional lymph node metastasis Positive Normal Thyroid US 1 
23 Female 52 Breast cancer Ductal carcinoma  Distant metastasis Positive Positive (no breast US examination), CEA 1 
24 Female 61 Breast cancer Ductal carcinoma  Localized Positive Positive  8 
25 Male 75 Liver Cancer Hepatocellular carcinoma Unknown Positive Positive Abdominal CT, US, AFP, CA19-9 5 
26 Male 67 Liver Cancer Hepatocellular carcinoma (mixed type) Localized Positive Positive  6 
27 Female 69 Liver Cancer Hepatocellular carcinoma Localized Positive Normal Abdominal US, AFP 2 
28 Female 69 Gall bladder cancer Unknown Unknown Positive Positive Abdominal CT, US, CA19-9 3 
29 Male 63 Gall bladder cancer Adenocarcinoma Localized Negative Normal   9 
30 Male 61 Gastric cancer Adenocarcinoma Regional lymph node metastasis Negative Normal Helicobacter pylori-antigen and Pepsinogen  4 
31 Male 70 Gastric cancer Adenocarcinoma Localized Negative Normal Helicobacter pylori-antigen and Pepsinogen  7 
32 Male 71 Bladder cancer Transitional cell carcinoma Localized Negative Normal  8 
33 Male 36 Testis cancer Unknown Unknown Positive Positive Pelvic MRI 2 
 
